Stocks Health care REPL
NASDAQ · Health careReplimune Group, Inc. (REPL)
It posted a net loss of $271M. In fiscal 2026 capital spending exceeded operating cash flow by $284.6M. At September 30, 2026 it held $307.8M in cash against $99.8M of debt. Its latest periodic report to the SEC is the quarterly report (amended) (10-Q/A) filed on November 6, 2026.
Key facts about Replimune Group, Inc.
- Net worth
- Replimune Group, Inc. has a market value (market cap) of $2.1B at the latest share price, and shareholders' equity of $204.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2026 operations used $280.3M of cash.
- Latest report
- The latest periodic report (quarterly report (amended), 10-Q/A) was filed with the SEC on November 6, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Replimune Group, Inc.'s next report is expected around February 2, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Replimune Group, Inc. does
Replimune Group, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker REPL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | n/a | -$313.9M | -$3.38 | -$284.6M |
| 2025 | n/a | -$247.3M | -$3.07 | -$198.9M |
| 2024 | n/a | -$215.8M | -$3.24 | -$191.1M |
| 2023 | n/a | -$174.3M | -$2.99 | -$130.3M |
| 2022 | n/a | -$118M | -$2.26 | -$84.5M |
| 2021 | n/a | -$80.9M | -$1.75 | -$63.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Replimune Group, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Passive stake changed SCHEDULE 13G/A
- November 6, 2026
- October 28, 2026
- October 28, 2026
- September 16, 2026
- August 14, 2026
- August 14, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026
- August 11, 2026Activist stake changed SCHEDULE 13D/A
Insider trades
What the people running Replimune Group, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $540.7K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 2, 2026 | Dhingra KapilDirector | Exercised options | 43,169 | $75.5K |
| November 2, 2026 | Dhingra KapilDirector | Sold | 21,500 | $408.5K |
| August 20, 2026 | Astley-Sparke PhilipDirector | Gave as a gift | 50,000 | - |
| August 17, 2026 | Hill Emily LuisaChief Financial Officer | Sold | 9,256 | $132.2K |
| August 10, 2026 | Schwendenman AndrewChief Accounting Officer | Sold | 7,632 | $99K |
| August 10, 2026 | Xynos KonstantinosChief Medical Officer | Sold | 11,447 | $148.5K |
| August 10, 2026 | Hill Emily LuisaChief Financial Officer | Sold | 11,448 | $148.5K |
| August 10, 2026 | Patel SushilChief Executive Officer, Director | Sold | 39,341 | $510.3K |
Who owns REPL
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Baker Bros. Advisors LP13D, may seek influence with 3 related filers | 11.8% | August 11, 2026 |
| RTW Investments, LP13G, passive with 1 related filers | 8.9% | May 15, 2026 |
| Ridgeback Capital Investments L.P.13G, passive with 2 related filers | 8.7% | August 14, 2026 |
| Montanova Capital, LLC13G, passive with 2 related filers | 7.9% | August 6, 2026 |
| Forbion Capital Fund III Coöperatief U.A.13G, passive with 1 related filers | 7.5% | November 14, 2024 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 199 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Baker Bros. Advisors LP | 11,045,336 | 0 |
| BlackRock, Inc. | 8,958,535 | +2,719,296 |
| Rtw Investments, LP | 7,411,581 | +54,665 |
| Ridgeback Capital Investments L.P. | 7,310,656 | new |
| Goldman Sachs Group Inc | 4,541,018 | +2,263,742 |
| State Street Corp | 4,440,144 | +657,907 |
| Montanova Capital, LLC | 4,389,836 | +168,000 |
| Boxer Capital Management, LLC | 3,983,000 | +2,808,000 |
| Vanguard Capital Management LLC | 2,896,004 | +136,884 |
| Fcpm III Services B.V. | 2,808,368 | 0 |
| Aqr Capital Management LLC | 2,566,241 | +2,310,746 |
| Logos Global Management LP | 2,500,000 | new |
| Jane Street Group, LLC | 2,322,545 | +1,894,400 |
| Erste Asset Management GmbH | 2,120,000 | 0 |
| Geode Capital Management, LLC | 2,035,187 | +233,662 |
| D. E. Shaw & Co., Inc. | 1,789,964 | -546,564 |
| Opaleye Management Inc. | 1,384,993 | new |
| Toronto Dominion Bank | 1,275,000 | -316,030 |
| UBS Group AG | 1,128,276 | +547,066 |
| Artisan Partners Limited Partnership | 973,496 | new |
Insiders
7 insiders reported holding 2,812,688 shares in total, about $62.6M at the last price.
| Holder | Shares |
|---|---|
| Astley-Sparke PhilipDirector | 1,362,414 |
| Patel SushilChief Executive Officer, Director | 708,151 |
| Xynos KonstantinosChief Medical Officer | 224,215 |
| Hill Emily LuisaChief Financial Officer | 215,852 |
| Sarchi ChristopherChief Commercial Officer | 180,962 |
| Schwendenman AndrewChief Accounting Officer | 99,425 |
| Dhingra KapilDirector | 21,669 |
Questions about REPL
What does Replimune Group, Inc. do?
Replimune Group, Inc. is a company in the Health care sector, listed on NASDAQ as REPL. Its shares trade on NASDAQ under the ticker REPL.
What is Replimune Group, Inc.'s net worth?
Replimune Group, Inc. has a market value (market cap) of $2.1B at the latest share price, and shareholders' equity of $204.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Replimune Group, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $271M.
When did Replimune Group, Inc. last report?
Its most recent periodic report is the quarterly report (amended) (10-Q/A) filed on November 6, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 9, 2026.
When is Replimune Group, Inc.'s next earnings report?
Replimune Group, Inc.'s next report is expected around February 2, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare REPL with
Follow REPL
Get an email when Replimune Group, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Replimune Group, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.